Nolan B. Seim

Assistant Professor

Ohio State University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (13)

Supplement Figure 3: Signature-based Biomarkers. A: Signature-Based biomarkers for HPV negative patients. B: Signature-based biomarkers for HPV positive patients. ‘Primary Path Response’ refers to analysis based on the pTR at the primary site alone. ‘Overall path response’ refers to analysis based on primary + lymph node response.

Year:

2025

Supplement Figure 1: Waterfall Plots. A: Degree of pathologic treatment response (pTR) at the lymph nodes. B: Degree of pathologic response at the primary site, stratifed by treatment arm. C: Degree of RECIST response of primary tumor site (yellow) and lymph nodes (purple), stratifed by treatment arm.

Year:

2025

Supplement Table 4A-4B: The following is a comprehensive list of the top 20 functional enrichments in the B cell (A) and CAF2 (B) gene sets utilizing STRING database to analyze protein-protein interaction pairs among the leading edge.

Year:

2025

Supplement Table 2A-2E: GSEA quantitative data for the B cell gene sets and CAF2 gene set for Post- vs Pre-treatments Responders vs Non responders. The following is a comprehensive list of supervised B-cell (A-C) and CAF (D-E) enrichment scores, normal enrichment scores, p-values, and q-values for the included gene sets.

Year:

2025

Supplementary Figure 2: Effect of IDO inhibitor BMS986205 on response rate and the tryptophan kynurenine pathway. A and B: IDO1 gene expression levels and tryptophan kynurenine pathway activity score, respectively, compared between baseline samples of responders (R) and non-responders (NR) on nivolumab + BMS986205 and nivolumab-only therapies. C: Tryptophan kynurenine pathway activity score compared between baseline and post-treatment samples of R and NR on nivolumab + BMS986205 and nivolumab-only therapies. - ns, *p

Year:

2025

Purpose: We evaluated whether indoleamine 2,3-dioxygenase (IDO1) inhibitor (IDOi) BMS986205 + PD-1 inhibitor nivolumab enhanced T-cell activity and augmented immune-mediated antitumor responses in untreated, resectable head and neck squamous cell carcinoma (HNSCC). We employed response-adaptive surgical timing to identify responders to immunotherapy and enhance their response. Patients and Methods: Patients with HNSCC were 3:1 randomized to receive nivolumab with or without BMS986205 orally daily (NCT03854032). In the combination arm, BMS986205 was initiated 7 days prior to nivolumab. Patients were stratified by human papillomavirus (HPV) status. Response-adaptive surgical timing involved response assessment by radiographic criteria 4 weeks after treatment with nivolumab in both arms. Nonresponders underwent surgical resection, whereas responders received 4 more weeks of randomized therapy before surgery. Biomarker analysis utilized pathologic treatment response (pTR) and RNA sequencing. Results: Forty-two patients were enrolled, and the addition of IDOi to nivolumab did not result in greater rate of radiographic response ( P = 0.909). Treatment was well tolerated, with only 2 (5%) patients experiencing grade 3 immune-related adverse events. The addition of IDOi augmented rates of pTR in patients with high baseline IDO1 RNA expression ( P P = 0.009). A pretreatment NK cell signature, PD-L1 status, and IFN-γ expression in the HPV − cohort correlated with response. The HPV + cohort found B-cell and cancer-associated fibroblast signatures predictive of response/nonresponse. Conclusions: Response-adaptive surgical timing enhanced treatment response. IDOi BMS986205 augmented pTR in patients with high IDO1 expression in baseline samples, indicating a need for identifying and targeting resistant nodes to immunotherapy. HPV status–dependent signatures predicting response to immunotherapy in HNSCC warrant further study.

Year:

2025

Supplement Table 4A-4B: The following is a comprehensive list of the top 20 functional enrichments in the B cell (A) and CAF2 (B) gene sets utilizing STRING database to analyze protein-protein interaction pairs among the leading edge.

Year:

2025

Supplement Table 2A-2E: GSEA quantitative data for the B cell gene sets and CAF2 gene set for Post- vs Pre-treatments Responders vs Non responders. The following is a comprehensive list of supervised B-cell (A-C) and CAF (D-E) enrichment scores, normal enrichment scores, p-values, and q-values for the included gene sets.

Year:

2025

Supplement Figure 1: Waterfall Plots. A: Degree of pathologic treatment response (pTR) at the lymph nodes. B: Degree of pathologic response at the primary site, stratifed by treatment arm. C: Degree of RECIST response of primary tumor site (yellow) and lymph nodes (purple), stratifed by treatment arm.

Year:

2025

Supplementary Figure 2: Effect of IDO inhibitor BMS986205 on response rate and the tryptophan kynurenine pathway. A and B: IDO1 gene expression levels and tryptophan kynurenine pathway activity score, respectively, compared between baseline samples of responders (R) and non-responders (NR) on nivolumab + BMS986205 and nivolumab-only therapies. C: Tryptophan kynurenine pathway activity score compared between baseline and post-treatment samples of R and NR on nivolumab + BMS986205 and nivolumab-only therapies. - ns, *p

Year:

2025

Year:

2025

Year:

2024

Year:

2022

Collaborators (15)

Andrew South

Oros Family Professor in Rare Skin Diseases

University of Wisconsin-Madison

UNITED STATES
View details

Rishabh Sethia

Assistant Professor

Nationwide Children's Hospital

UNITED STATES
View details

David Cognetti

department of surgery thomas jefferson university hospital sidney kimmel medical college philadelphia university and tho

UNITED STATES
View details

Joseph Curry

Associate Professor

Thomas Jefferson University Hospital

UNITED STATES
View details

Tingting Zhan

Associate Professor

Thomas Jefferson University

UNITED STATES
View details

Rita Axelrod

Professor

Thomas Jefferson University

UNITED STATES
View details

George Prendergast

Professor, President & CEO

Lankenau Institute for Medical Research

UNITED STATES
View details

Kyle K. VanKoevering

Assistant Professor

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Benjamin Leiby

Professor

Thomas Jefferson University

UNITED STATES
View details

Larry Harshyne

Associate Professor

Thomas Jefferson University

UNITED STATES
View details

Jennifer M. Johnson

Thomas Jefferson University

UNITED STATES
View details

Moataz Desouky Abouammo

Research Associate / Researcher 1

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Ubaldo Martinez-Outschoorn

Associate Professor

Thomas Jefferson University

UNITED STATES
View details

Stacey Gargano

Thomas Jefferson University Hospital

UNITED STATES
View details

Adam J. Luginbuhl

-

UNITED STATES
View details